Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65

  • Shihui Li
  • Fang Xue
  • Zhiyong Cheng
  • Xiaoyang Yang
  • Suyun Wang
  • Fengyong Geng
  • Ling Pan
Original Article

Abstract

The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes. High dose therapy and autologous stem cell transplantation remain an important therapeutic option for patients with MM eligible for the procedure. However, most of these treatment regimens are too expensive for Chinese patients. Therefore, we investigated the effects of artesunate, which is commonly used in the treatment of severe malaria, on inhibition of proliferation and induction of apoptosis of a mouse myeloma cell line SP2/0. The growth inhibition of SP2/0 cell proliferation induced by artesunate (ART) treatment was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the rate of apoptosis and cell cycle changes induced by ART were analyzed by flow cytometry. ART-induced morphology changes of apoptosis in SP2/0 cells, as observed by light and transmission electron microscopy. Additionally, DNA laddering, which is a hallmark of apoptosis, was observed by agarose gel electrophoresis of DNA harvested from SP2/0 cells treated with ART. The levels of nuclear factor kappa B p65 (NFκB p65) protein in nucleus and the inhibitor of NFκB (IκBα) in the cytoplasm were measured by western blot analysis and ELISA to evaluate NFκB p65 transcription activity indirectly. The results show that artesunate inhibited the proliferation and induced apoptosis of SP2/0 cells in a dose- and time-dependent manner. Artesunate also increased the proportion of SP2/0 cells in G0/G1 phase, while decreased the proportion of cells in G2/M or S phase. Additionally, artesunate treatment decreased the level of NFκB p65 protein in the nucleus, while increased the level of IκBα protein in the cytoplasm. The present result is the first report to show that artesunate may be useful in the treatment of MM.

Keywords

Artesunate Multiple myeloma Apoptosis Proliferation Nuclear factor kappa B 

References

  1. 1.
    Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.PubMedGoogle Scholar
  2. 2.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol. 2003;77:226–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91:1722–3.PubMedGoogle Scholar
  8. 8.
    Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Richardson PG, Barlogie B, Berenson J, Irwin D, Stadtmauer EA, Facon T, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.CrossRefPubMedGoogle Scholar
  11. 11.
    Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv Pharmacol. 1997;37:253–97.CrossRefPubMedGoogle Scholar
  14. 14.
    Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis. 2003;188:1231–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate–atovaquone–proguanil. Clin Infect Dis. 2002;35:1498–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18:767–73.PubMedGoogle Scholar
  17. 17.
    Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64:382–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Efferth T, Benakis A, Romero-Rodriguez MR, Tomicic M, Rauh R, Steinbach D, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004;37:998–1009.CrossRefPubMedGoogle Scholar
  19. 19.
    Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem. 2004;47:1299–301.CrossRefPubMedGoogle Scholar
  20. 20.
    Suzuki A, Shiraki K. Tumor cell “dead or alive”: caspase and surviving regulate cell death, cell cycle and cell survival. Histol Histopathol. 2001;16:583–93.PubMedGoogle Scholar
  21. 21.
    Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28:626–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–27.CrossRefPubMedGoogle Scholar
  24. 24.
    Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-кB activity by thalidomide through suppression of IкB kinase activity. J Biol Chem. 2001;276:22382–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhou LF, Zhu Y, Cui XF, Xie WP, Hu AH, Yin KS. Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation. Respir Res. 2006;20:146–9.CrossRefGoogle Scholar
  27. 27.
    Lemarie A, Morzadec C, Mérino D, Micheau O, Fardel O, Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB related survival pathway down-regulation. J Pharmacol Exp Ther. 2006;316:304–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, et al. s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5:247–54.CrossRefPubMedGoogle Scholar
  29. 29.
    Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50:183–93.PubMedGoogle Scholar
  30. 30.
    St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996;2:1204–10.CrossRefPubMedGoogle Scholar
  31. 31.
    St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 Kip1. J Cell Biol. 1998;142:557–71.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Shihui Li
    • 1
  • Fang Xue
    • 1
  • Zhiyong Cheng
    • 1
  • Xiaoyang Yang
    • 2
  • Suyun Wang
    • 1
  • Fengyong Geng
    • 3
  • Ling Pan
    • 1
  1. 1.Department of HematologyThe Second Hospital of Hebei Medical UniversityShijiazhuang CityPeople’s Republic of China
  2. 2.Department of Hematology, Affiliated Haikou Hospital, Xiangya School of MedicineCentral South University, Haikou Municipal HospitalHaikouPeople’s Republic of China
  3. 3.Department of General SurgeryAviation Central HospitalPeking CityPeople’s Republic of China

Personalised recommendations